Fu W - Search Results

1

Targeted delivery of CD44s-siRNA by ScFv overcomes de novo resistance to cetuximab in triple negative breast cancer.

Fu W, Sun H, Zhao Y, Chen M, Yang L, Yang X, Jin W. Fu W, et al. Mol Immunol. 2018 Jul;99:124-133. doi: 10.1016/j.molimm.2018.05.010. Epub 2018 May 16. Mol Immunol. 2018. PMID: 29777999

2

Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer.

Hu S, Dai H, Li T, Tang Y, Fu W, Yuan Q, Wang F, Lv G, Lv Y, Fan X, Zhang S, Jin R, Shen Y, Lin F, Ye X, Ding M, Yang Y, Lei C. Hu S, et al. Among authors: fu w. Cancer Lett. 2016 Nov 1;382(1):32-43. doi: 10.1016/j.canlet.2016.08.022. Epub 2016 Aug 26. Cancer Lett. 2016. PMID: 27569653

3

Antagonism of EGFR and Notch limits resistance to EGFR inhibitors and radiation by decreasing tumor-initiating cell frequency.

Hu S, Fu W, Li T, Yuan Q, Wang F, Lv G, Lv Y, Fan X, Shen Y, Lin F, Tang Y, Ye X, Yang Y, Lei C. Hu S, et al. Among authors: fu w. Sci Transl Med. 2017 Mar 8;9(380):eaag0339. doi: 10.1126/scitranslmed.aag0339. Epub 2017 Mar 8. Sci Transl Med. 2017. PMID: 28275151

4

High expression of COX5B is associated with poor prognosis in breast cancer.

Gao SP, Sun HF, Fu WY, Li LD, Zhao Y, Chen MT, Jin W. Gao SP, et al. Among authors: fu wy. Future Oncol. 2017 Aug;13(19):1711-1719. doi: 10.2217/fon-2017-0058. Epub 2017 Jun 8. Future Oncol. 2017. PMID: 28592145

5

UHRF1 promotes breast cancer progression by suppressing KLF17 expression by hypermethylating its promoter.

Gao SP, Sun HF, Li LD, Fu WY, Jin W. Gao SP, et al. Among authors: fu wy. Am J Cancer Res. 2017 Jul 1;7(7):1554-1565. eCollection 2017. Am J Cancer Res. 2017. PMID: 28744404 Free PMC article.

6

Comparison of patterns and prognosis among distant metastatic breast cancer patients by age groups: a SEER population-based analysis.

Chen MT, Sun HF, Zhao Y, Fu WY, Yang LP, Gao SP, Li LD, Jiang HL, Jin W. Chen MT, et al. Among authors: fu wy. Sci Rep. 2017 Aug 23;7(1):9254. doi: 10.1038/s41598-017-10166-8. Sci Rep. 2017. PMID: 28835702 Free PMC article.

7

Clinicopathological characteristics and survival outcomes of male breast cancer according to race: A SEER population-based study.

Sun HF, Zhao Y, Gao SP, Li LD, Fu WY, Jiang HL, Chen MT, Yang LP, Jin W. Sun HF, et al. Among authors: fu wy. Oncotarget. 2017 May 26;8(41):69680-69690. doi: 10.18632/oncotarget.18265. eCollection 2017 Sep 19. Oncotarget. 2017. PMID: 29050233 Free PMC article.

8

Trends and outcomes of neoadjuvant radiotherapy compared with postoperative radiotherapy for malignant breast cancer.

Fu W, Sun H, Zhao Y, Chen M, Yang L, Gao S, Li L, Jin W. Fu W, et al. Oncotarget. 2018 May 11;9(36):24525-24536. doi: 10.18632/oncotarget.24313. eCollection 2018 May 11. Oncotarget. 2018. PMID: 29849958 Free PMC article.

9

BCAP31 drives TNBC development by modulating ligand-independent EGFR trafficking and spontaneous EGFR phosphorylation.

Fu W, Sun H, Zhao Y, Chen M, Yang X, Liu Y, Jin W. Fu W, et al. Theranostics. 2019 Aug 21;9(22):6468-6484. doi: 10.7150/thno.35383. eCollection 2019. Theranostics. 2019. PMID: 31588230 Free PMC article.

10

Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk.

Hu S, Fu W, Xu W, Yang Y, Cruz M, Berezov SD, Jorissen D, Takeda H, Zhu W. Hu S, et al. Among authors: fu w. Cancer Res. 2015 Jan 1;75(1):159-70. doi: 10.1158/0008-5472.CAN-14-1670. Epub 2014 Nov 4. Cancer Res. 2015. PMID: 25371409

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6,443 results

Search Page

Filters